Full-Time

Senior Manager

Clinical Management

 Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharmaceutical company developing medicines

Compensation Overview

$150k - $224.3k/yr

+ Incentive opportunity

Remote in USA

Remote

Travel up to 25% may be required.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
Word/Pages/Docs
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • Comprehensive knowledge of clinical operations, the drug development process, project team roles and responsibilities, standard operating procedures, and Good Clinical Practice and International Council for Harmonisation regulations.
  • Thorough knowledge of contract research organizations, outsourcing, and evaluating vendor work against Statements of Work.
  • Strong understanding of the clinical and scientific basis for the assigned clinical program, with the ability to translate that knowledge into operational management.
  • Strong understanding of global regulatory requirements.
  • Strong communication, organization, planning, analytical, problem-solving, and people-management skills.
  • Demonstrated experience working with Microsoft programs, including Word, Excel, PowerPoint, and Outlook.
  • Good understanding of clinical-trial software, including electronic case report forms, interactive response technology, and clinical trial management systems.
  • Ability to travel up to 25%.
  • Bachelor's Degree or Registered Nurse (RN).
  • At least 10 years of industry experience, including seven years of clinical trial management experience.
Responsibilities
  • Provide oversight and management of clinical studies, including planning, execution, and completion of clinical trials according to applicable regulations and guidance, International Council for Harmonisation Good Clinical Practices, and Otsuka standard operating procedures.
  • Contribute to the development and review of critical clinical study documents, including clinical protocols, informed consent forms, and other study-related clinical documents.
  • Provide input into and approve the identification, evaluation, and selection of contract research organizations, outside vendors, and investigative sites.
  • Provide leadership and guidance to the clinical team to ensure clinical study activities comply with applicable regulations and guidance, International Council for Harmonisation Good Clinical Practice, and Otsuka standard operating procedures.
  • Communicate and coordinate clinical project activities and progress across relevant cross-functional departments.
  • Provide management personnel with timely updates on progress and changes in scope, schedule, and resources.
  • Participate in forecasting study expenditures and resourcing needs.
  • Ensure the internal clinical team and vendors manage and monitor study-related budgets and expenses to meet the forecast.
  • Communicate budget-forecast variances to the Director or Associate Director in a timely manner.
  • Establish communication flow with contract research organizations and investigative sites to maximize compliance with the study protocol.
  • Provide oversight of external service providers in the day-to-day operations of assigned trials.
  • Participate in ongoing review of clinical-trial data, focusing on data integrity, trending, and consistency.
  • Support project-level inspection-readiness activities, including ensuring the completeness, timeliness, and quality of the Trial Master File.
  • Serve as the Clinical Management representative for protocol reviews within and across portfolios.
  • Participate in program-level risk-mitigation strategies and collaborate with external service providers on study-level risk-mitigation and management activities.
  • Represent Clinical Management in departmental and cross-functional initiatives.
  • Lead or contribute to departmental, external service provider, and corporate standardization and continuous-improvement efforts.
  • Coordinate training and onboarding of new employees on corporate culture, corporate goals and vision, and departmental policies and processes.
  • Ensure assigned staff complete required departmental, standard operating procedure, compliance, and corporate training.
  • Ensure assigned staff have access to required materials, systems, and training to complete their job responsibilities.
  • Set clear performance expectations and individual development plans and provide specific and frequent performance feedback to employees.
Desired Qualifications
  • Previous supervisory experience.
 Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical is a global health-focused company that develops and markets medicines and nutraceutical products. It creates pharmaceuticals like Abilify (aripiprazole), an antipsychotic, and consumer health brands such as Pocari Sweat, an ion-replacement drink. Its products work by medical mechanisms (Abilify modulates dopamine and serotonin receptors to treat psychiatric conditions) and by supporting hydration and electrolyte balance (Pocari Sweat). Otsuka differentiates itself through a long, international growth path from its roots as a Japanese chemical manufacturer, a balanced portfolio spanning prescription drugs and health beverages, and a philosophy of developing new products to improve health worldwide. Its goal is to deliver healthier outcomes for people around the world by expanding access to innovative medicines and health-related consumer products.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 Simtriyo approval opens ADHD commercialization across adults and children six-plus.
  • VOYXACT posted 82.5% hematuria improvement at 48 weeks, strengthening Otsuka’s nephrology franchise.
  • Japan coverage for Paradise renal denervation and Dawnzera EU approval broaden near-term revenue streams.

What critics are saying

  • May 21, 2026 Lupin win weakens JYNARQUE patents before generic erosion accelerates.
  • Nuedexta’s patent expires August 13, 2026, inviting Hetero launch pressure.
  • TSND-201 and Simtriyo still need flawless execution; one failure damages Otsuka’s growth story.

What makes Otsuka Pharmaceutical unique

  • Otsuka spans psychiatry, nephrology, and consumer health, unlike single-therapy biotech peers.
  • June 12, 2026 Transcend acquisition deepens its rapid-acting neuropsychiatry platform.
  • January 21, 2026 Towa supply agreement protects manufacturing continuity in Japan.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.